SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Arthur Klausner to speak at FundingPost's early-stage VC breakfast in New York City on May 18
News | 05. 18. 2006
